H.C. Wainwright analyst Swayampakula Ramakanth lowered the firm’s price target on Asensus Surgical to $2 from $3 and keeps a Buy rating on the shares following the Q4 results. With "continued financial market pressures," the analyst lowered lease conversion expectations for 2023 and 2024.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ASXC:
- Asensus Surgical to Participate in the Oppenheimer 33rd Annual Healthcare Conference
- Asensus Surgical, Inc. Reports Operating and Financial Results for the Fourth Quarter and Full Year 2022
- Asensus Surgical, Inc. to Release Fourth Quarter and Full Year 2022 Financial and Operating Results on March 2, 2023
- Asensus Surgical Provides Corporate Update
- Asensus Surgical to host virtual investor day